Quietiapin (seroquel) jämfört med andra antipsykotiska mediciner

Available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks (around 60%).

Comparisons with amisulpride, sertindole and zotepine do not exist.

Although efficacy data favour olanzapine and risperidone compared with quetiapine, the clinical meaning of these data remains unclear.

Quetiapine may produce fewer parkinsonian effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine.

Quetiapine appears to have a similar weight gain profile to risperidone, as well as clozapine and aripiprazole (although data are very limited for the latter two comparators).

Quetiapine may produce greater weight gain than ziprasidone and less weight gain than olanzapine and paliperidone.

Most data that have been reported within existing comparisons are of very limited value because of assumptions and biases within them.